8-K: Elicio Therapeutics Reports Positive Phase 1 Data and Secures Funding into 2025

Elicio Therapeutics announced encouraging Phase 1 clinical trial results for its ELI-002 7P cancer immunotherapy, along with securing funding to extend operations into the second quarter of 2025.

Summary

• Elicio Therapeutics reported its second quarter 2024 financial results and provided corporate updates, highlighting progress with its ELI-002 cancer immunotherapy program.
• The company's AMPLIFY-7P Phase 1 trial showed a strong correlation between T-cell response and reduced risk of disease progression or death.
• Data presented at ASCO demonstrated that 100% of patients developed mKRAS-specific T-cell responses, with approximately 66% showing both CD4+ and CD8+ T-cell involvement.
• The company is minimizing long-term follow-up for the AMPLIFY-7P Phase 1 study to conserve resources, with updated data to be shared at future medical meetings.
• Enrollment for the AMPLIFY-7P Phase 2 randomized clinical trial is expected to complete with 135 patients in the fourth quarter of 2024.
• Elicio raised $43 million in 2024, which is expected to fund operations into the second quarter of 2025.
• The company's research and development expenses increased to $8.2 million in the second quarter of 2024, up from $4.9 million in the same period of 2023, primarily due to increased clinical trial costs.
• Elicio reported a net loss of $7.2 million for the second quarter of 2024, compared to a $7.6 million loss in the second quarter of 2023.
• Cash and cash equivalents were $3.4 million as of June 30, 2024, but this does not include $9.9 million from a public offering received on July 1, 2024, and $19.7 million from a convertible note financing received on August 12, 2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial data and secures funding, indicating a strong outlook for the company. The high T-cell response rate and lack of serious adverse events are particularly encouraging.

Positives

• The ELI-002 7P formulation is well-tolerated and generates a significantly larger T-cell response compared to the 2-peptide formulation.
• The ELI-002 7P immune response included both CD4+ and CD8+ T-cells and generated antigen-spreading.
• Patients achieving a reduction in their tumor biomarker levels had no progression events.
• No dose-limiting toxicities, treatment-related serious adverse events, or cytokine release syndrome were observed in the AMPLIFY-7P Phase 1 trial.
• The company has secured funding into the second quarter of 2025.

Negatives

• The company reported a net loss of $7.2 million for the second quarter of 2024.
• Cash and cash equivalents were $3.4 million as of June 30, 2024, which is a decrease from $12.9 million as of December 31, 2023.
• The company is winding down the Phase 1 trials after a final data cut later this summer.

Risks

• The company's financial condition, including its cash runway, is dependent on securing additional funding to advance the development of ELI-002 and other product candidates.
• The company's ability to continue as a going concern is dependent on securing additional funding.
• The timing of clinical trial initiations and data availability is subject to change.
• The clinical utility and market acceptance of Elicio's product candidates are not guaranteed.
• The company faces competition from other biotechnology companies in the industry.
• The company's ability to protect its intellectual property is crucial for its success.

Future Outlook

Elicio anticipates completing enrollment in the AMPLIFY-7P Phase 2 trial in the fourth quarter of 2024, with an interim analysis expected in the first quarter of 2025. The company also plans to provide updated data from the AMPLIFY-201 and AMPLIFY-7P trials at upcoming medical meetings.

Management Comments

• Robert Connelly, CEO, stated that they are encouraged by the early clinical data from the ELI-002 Phase 1 trial and energized by the enrollment rate in the ongoing Phase 2 trial.
• Robert Connelly, CEO, mentioned that the company is funded into the second quarter of 2025, beyond when they expect to have the interim analysis readout of the ongoing randomized Phase 2 trial of ELI-002 monotherapy in PDAC.
• Christopher Haqq, CMO, noted that the 7-peptide formulation is well-tolerated and generates a significantly larger T-cell response compared to the 2-peptide formulation.

Industry Context

Elicio's focus on lymph node-targeted immunotherapies aligns with the growing interest in enhancing the immune system's ability to fight cancer. The positive Phase 1 data for ELI-002 7P, particularly the strong T-cell response, positions Elicio as a potential player in the competitive immuno-oncology space.

Comparison to Industry Standards

• Elicio's 100% T-cell response rate in the AMPLIFY-7P Phase 1 trial is a strong result compared to other cancer immunotherapy trials, where response rates can vary significantly.
• The observation of both CD4+ and CD8+ T-cell responses is also a positive indicator, as both types of T-cells play important roles in anti-tumor immunity.
• The company's approach of targeting multiple KRAS mutations with the 7-peptide formulation is a strategy to address the heterogeneity of KRAS-driven cancers, which is a common challenge in the field.
• While specific comparisons to other companies' results are not provided in the document, the data suggests that Elicio's AMP platform is showing promising results in terms of immune response and tolerability.
• Companies like Mirati Therapeutics and Amgen are also developing KRAS inhibitors, but Elicio's approach is different, focusing on stimulating the immune system to target cancer cells.

Stakeholder Impact

• Shareholders may view the positive clinical data and secured funding as positive developments.
• Employees may be encouraged by the company's progress and financial stability.
• Patients with mKRAS-driven cancers may benefit from the development of ELI-002.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Elicio will conduct a final data cut for the Phase 1 trials later this summer.
• The company will share longer-term follow-up data at upcoming medical meetings.
• Elicio expects to complete enrollment in the AMPLIFY-7P Phase 2 trial in the fourth quarter of 2024.
• The company will provide updated immunogenicity and relapse-free survival data from the AMPLIFY-201 trial in the fourth quarter of 2024.
• Elicio will provide updated preliminary DFS data from the ELI-002 7P monotherapy Phase 1a arm in the first quarter of 2025.
• The company expects an interim analysis from the Phase 2 AMPLIFY-7P trial in the first quarter of 2025.

Key Dates

Keywords

immunotherapy, cancer, clinical trials, T-cell response, mKRAS, ELI-002, biotechnology, lymph node, AMP platform, Phase 1, Phase 2, funding